China has completed clinical research on a drug Favipiravir, An antiviral drug that showed good clinical efficacy against the Corona virus (COVID-19), A Chinese official said Tuesday.
Zhang Xinmin, director of the China National Center for Biotechnology Development under the Ministry of Science and Technology, said that faviravir, the influenza drug approved for clinical use in Japan in 2014, showed no clear negative reactions in the clinical trial, but rather made its recipient less responsive to infection opportunities With the virus.
According to the Xinhua News Agency, more than 80 patients participated in the clinical trial at the Third People’s Hospital in Shenzhen, south China’s Guangdong Province, including 35 patients who took faviravir and 45 patients in a control group. The results showed that patients receiving faviravir treatment became passive to the virus in a shorter time compared to patients in the control group.
A multicenter randomized clinical study conducted by a hospital revealed Zhongnan Wuhan University that the therapeutic effect of Favipiravir Much better than the control group effect.
Zhang said that faviravir should be included in the diagnosis and treatment plan for COVID-19 as soon as possible.
Zhang added that the Chinese Medical Products Administration had agreed to a Chinese pharmaceutical company to mass-produce the drug and ensure stable supply.
– .
